

Alastair J Hutchison

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8745576/alastair-j-hutchison-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72 papers	2,466 citations	30 h-index	49 g-index
76 ext. papers	2,679 ext. citations	4.6 avg, IF	4.69 L-index

#	Paper	IF	Citations
72	Prescribing high-quality peritoneal dialysis: Moving beyond urea clearance. <i>Peritoneal Dialysis International</i> , 2020 , 40, 293-301	2.8	
71	A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis. <i>BMC Nephrology</i> , 2019 , 20, 37	2.7	8
70	Hyperphosphataemia in 2019: have we made progress?. <i>Current Opinion in Nephrology and Hypertension</i> , 2019 , 28, 441-447	3.5	3
69	Long-Term Mortality and Bone Safety in Patients with End-Stage Renal Disease Receiving Lanthanum Carbonate. <i>Nephron</i> , 2018 , 140, 265-274	3.3	8
68	A Multifaceted Quality Improvement Programme to Improve Acute Kidney Injury Care and Outcomes in a Large Teaching Hospital. <i>BMJ Quality Improvement Reports</i> , 2017 , 6,		23
67	Peritoneal Dialysis Solutions 2017 , 408-417.e1		0
66	Lanthanum carbonate: safety data after 10 years. <i>Nephrology</i> , 2016 , 21, 987-994	2.2	41
65	A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on Dialysis. <i>International Journal of Nephrology</i> , 2015 , 2015, 579434	1.7	4
64	Acute arteriovenous access failure: long-term outcomes of endovascular salvage and assessment of co-variables affecting patency. <i>Nephron</i> , 2015 , 129, 241-6	3.3	9
63	Variability in parathyroid hormone assays confounds clinical practice in chronic kidney disease patients. <i>Annals of Clinical Biochemistry</i> , 2014 , 51, 228-36	2.2	7
62	Incidence and consequence of acute kidney injury in unselected emergency admissions to a large acute UK hospital trust. <i>BMC Nephrology</i> , 2014 , 15, 84	2.7	46
61	Profiling patient attitudes to phosphate binding medication: a route to personalising treatment and adherence support. <i>Psychology and Health</i> , 2014 , 29, 1407-20	2.9	14
60	Novel phosphate binders: plus ça change, plus c'est la même chose. <i>Kidney International</i> , 2014 , 86, 471-4	9.9	6
59	Outcomes of peritoneal dialysis patients and switching to hemodialysis: a competing risks analysis. <i>Peritoneal Dialysis International</i> , 2014 , 34, 289-98	2.8	24
58	Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients. <i>BMC Nephrology</i> , 2013 , 14, 40	2.7	11
57	Use of magnesium as a drug in chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2012 , 5, i62-i70	4.5	13
56	Enabling self-management: selecting patients for home dialysis?. <i>CKJ: Clinical Kidney Journal</i> , 2011 , 4, iii7-iii10	4.5	2

55	Pharmacology, efficacy and safety of oral phosphate binders. <i>Nature Reviews Nephrology</i> , 2011 , 7, 578-89	4.9	70
54	Update and critical appraisal of sevelamer in the management of chronic renal failure. <i>Open Access Journal of Urology</i> , 2010 , 2, 161-70		9
53	Cardiovascular disease in patients with chronic kidney disease. <i>Vascular Health and Risk Management</i> , 2009 , 5, 713-22	4.4	58
52	Oral phosphate binders. <i>Kidney International</i> , 2009 , 75, 906-14	9.9	81
51	Lanthanum carbonate for hyperphosphatemia in patients with advanced CKD and patients receiving dialysis. <i>Expert Review of Endocrinology and Metabolism</i> , 2009 , 4, 307-316	4.1	
50	Lanthanum and phosphate: science, policy, and survival. <i>Kidney International</i> , 2009 , 75, 355-7	9.9	2
49	Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 401-9	6.9	30
48	Oral phosphate binders for the management of serum phosphate levels in dialysis patients. <i>Journal of Renal Care</i> , 2009 , 35 Suppl 1, 65-70	1.6	12
47	Calcium and Magnesium Flux in Automated Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2009 , 29, 536-541	2.8	9
46	Calcium and magnesium flux in automated peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2009 , 29, 536-41	2.8	5
45	Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. <i>Nephron Clinical Practice</i> , 2008 , 110, c15-23		90
44	Encapsulating peritoneal sclerosis following renal transplantation despite tamoxifen and immunosuppressive therapy. <i>CKJ: Clinical Kidney Journal</i> , 2008 , 1, 333-5	4.5	1
43	Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 3677-84	4.3	46
42	Nutritional Management of Patients Undergoing Surgery following Diagnosis with Encapsulating Peritoneal Sclerosis. <i>Peritoneal Dialysis International</i> , 2008 , 28, 271-276	2.8	31
41	Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate. <i>Therapeutics and Clinical Risk Management</i> , 2008 , 4, 887-93	2.9	18
40	Peritoneal Dialysis Solutions 2008 , 558-568		
39	Proximal calciphylaxis treated with calcimimetic Cinacalcet <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 387-9	4.3	56
38	Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis. <i>Peritoneal Dialysis International</i> , 2008 , 28, 271-6	2.8	12

37	Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed?. <i>Seminars in Dialysis</i> , 2007 , 20, 24-32	2.5	3
36	Opinion: Which of the K/DOQI Guidelines for Bone Disease in Dialysis Patients Should be Changed?. <i>Seminars in Dialysis</i> , 2007 , 20, 26-28	2.5	
35	Lanthanum carbonate--a first line phosphate binder?. <i>Seminars in Dialysis</i> , 2007 , 20, 325-8	2.5	10
34	Dialysate calcium and calcium/phosphate balance in hemodialysis. <i>Hemodialysis International</i> , 2007 , 11, S27-S33	1.7	
33	Quality of life in CAPD, transplant, and chronic renal failure patients with diabetes. <i>Renal Failure</i> , 2007 , 29, 189-97	2.9	15
32	Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. <i>Nephron Clinical Practice</i> , 2006 , 102, c61-71		79
31	Severe acute renal failure in adults: place of care, incidence and outcomes. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005 , 98, 661-6	2.7	36
30	Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 319-28	4	40
29	Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. <i>Kidney International</i> , 2005 , 68, 2381-8	9.9	117
28	Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. <i>International Journal of Clinical Practice</i> , 2005 , 59, 1091-6	2.9	56
27	Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. <i>Nephrology Dialysis Transplantation</i> , 2005 , 20, 775-82	4.3	47
26	Improving phosphate-binder therapy as a way forward. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19 Suppl 1, i19-24	4.3	36
25	Reducing dialysate calcium - a reasonable strategy?. <i>Nephron Clinical Practice</i> , 2004 , 96, c1-2		2
24	Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 1902-6	4.3	64
23	Decrease in infections with the introduction of mupirocin cream at the peritoneal dialysis catheter exit site. <i>Journal of Nephrology</i> , 2004 , 17, 242-5	4.8	22
22	Bone histopathology and densitometry comparison between cyclosporine a monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients. <i>Transplantation</i> , 2003 , 75, 2053-8	1.8	45
21	A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. <i>Kidney International</i> , 2003 , S73-8	9.9	237
20	Hyperphosphataemia in renal failure: causes, consequences and current management. <i>Drugs</i> , 2003 , 63, 577-96	12.1	55

19	Dialysis therapies for end-stage renal disease. <i>Seminars in Dialysis</i> , 2002 , 15, 220-6	2.5	13
18	Side-effects of antituberculosis drug treatment in patients with chronic renal failure. <i>European Respiratory Journal</i> , 2002 , 20, 440-3	13.6	23
17	Association of sex hormone status with the bone loss of renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 1245-50	4.3	12
16	Peritoneal tuberculosis in patients receiving continuous ambulatory peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 1024-7	4.3	42
15	Recurrent <i>Escherichia coli</i> bacteraemia in a patient with chronic renal failure. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16, 2429-30	4.3	1
14	Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. <i>Kidney International</i> , 2000 , 58, 1440-9	9.9	97
13	Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. <i>American Journal of Kidney Diseases</i> , 2000 , 35, 227-36	7.4	76
12	Bone loss in long-term renal transplantation: histopathology and densitometry analysis. <i>Kidney International</i> , 1999 , 55, 2021-9	9.9	105
11	Predialysis management of divalent ion metabolism. <i>Kidney International</i> , 1999 , 73, S82-4	9.9	5
10	Low Turnover Bone Disease. <i>Peritoneal Dialysis International</i> , 1996 , 16, 295-299	2.8	9
9	Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 1996 , 11, 2430-8	4.3	59
8	Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations. <i>Nephron</i> , 1996 , 72, 52-8	3.3	25
7	Increased mortality due to cardiovascular disease in type 1 diabetic patients transplanted for end-stage renal failure. <i>Diabetic Medicine</i> , 1994 , 11, 987-91	3.5	15
6	Histological, radiological, and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis patients. <i>American Journal of Nephrology</i> , 1994 , 14, 19-29	4.6	53
5	Calcium, phosphate and renal osteodystrophy 1994 , 529-553		1
4	Calcium and Magnesium Mass Transfer in Peritoneal Dialysis Patients Using 1.25 Mmol/L Calcium, 0.25 Mmol/L Magnesium Dialysis Fluid. <i>Peritoneal Dialysis International</i> , 1993 , 13, 219-223	2.8	35
3	Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. <i>Kidney International</i> , 1993 , 44, 1071-7	9.9	168
2	Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. <i>Nephrology Dialysis Transplantation</i> , 1992 , 7, 1219-25	4.3	69

- 1 Risk factors for non-ischaemic foot ulceration in diabetic nephropathy. *Diabetic Medicine*, **1991**, 8, 223-5 3.5 45